2 results
Approved WMOCompleted
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…
Approved WMOPending
The primary objective of this clinical performance study is to evaluate the effectiveness of the B7-H4 (A57.1) CTA in identifying B7-H4 positive (B7-H4 membrane staining at any intensity in >=25% tumor cells) ovarian, endometrial, biliary…